One-year outcomes at a specialized referral center show potential diagnostic pitfalls.
Recent studies and consensus groups have highlighted the problem of misdiagnosis in multiple sclerosis (MS). Investigators prospectively reviewed all new patients referred to an MS center during a 1-year period. The cohort included 354 patients with 1 year of follow-up.
On the referral form, 112 patients had an “established diagnosis” of MS, and 77 had “suspected MS.” Of those with “established MS” at referral, the diagnosis was changed to non-MS after 1 year of follow-up in 8 and to suspected MS in 6. Of the 77 with “suspected MS” at referral, at 1-year follow-up 37 were determined to have MS, 15 still had suspected MS, and 25 did not have MS. Of those referred with “established MS” subsequently deemed as misdiagnosed, 64% were on a disease…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)